Dr. Kim

Lyndon J. Kim, MD

Contact Dr. Kim

900 Walnut Street
Suite 200
Philadelphia, PA 19107

(215) 955-7000

Most Recent Peer-reviewed Publications

  1. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment
  2. Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)
  3. Ependymomas overexpress chemoresistance and DNA repairrelated proteins
  4. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244
  5. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
  6. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas
  7. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better
  8. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
  9. A phase 2 trial of verubulin for recurrent glioblastoma: A prospective study by the brain tumor investigational consortium (BTIC)
  10. The potential role of magnetic resonance spectroscopy in image-guided radiotherapy
  11. Chemoirradiation for Glioblastoma Multiforme: The National Cancer Institute Experience
  12. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: Prognosis and identification by111indium-octreotide imaging
  13. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas
  14. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
  15. Primary brain tumors: Characteristics, practical diagnostic and treatment approaches
  16. A phase I trial of enzastaurin in patients with recurrent gliomas
  17. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
  18. Erratum: Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme (Journal of Neuro-Oncology (2008) vol. 89 (339-357) 10.1007/s11060-008-9615-4)
  19. Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme
  20. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors